For research use only. Not for therapeutic Use.
Hydroxyurea（Cat No.:A000303）is an antineoplastic and antimetabolite drug used primarily in the treatment of certain cancers, such as chronic myelogenous leukemia (CML) and ovarian cancer, as well as sickle cell anemia. It works by inhibiting ribonucleotide reductase, an enzyme critical for DNA synthesis, leading to reduced production of deoxyribonucleotides and halting DNA replication. This results in cell cycle arrest, especially in rapidly dividing cancer cells. Hydroxyurea also helps increase fetal hemoglobin levels in sickle cell disease, reducing the severity of symptoms. Common side effects include bone marrow suppression, gastrointestinal issues, and skin rashes.
| Catalog Number | A000303 |
| CAS Number | 127-07-1 |
| Synonyms | ci-c04831, nsc32065 |
| Molecular Formula | CH4N2O2 |
| Purity | ≥95% |
| Target | Autophagy |
| Storage | 3 years -20C powder |
| IUPAC Name | hydroxyurea |
| InChI | InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) |
| InChIKey | VSNHCAURESNICA-UHFFFAOYSA-N |
| SMILES | C(=O)(N)NO |
| Reference | Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the Treatment of Sickle Cell Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Feb. (Evidence Reports/Technology Assessments, No. 165.) 1, Introduction. Available from: http://www.ncbi.nlm.nih.gov/books/NBK38503/</span></p> |
